Original practice scenario: A hypothetical diagnostics interface receives preliminary, corrected and repeated result messages. Design matching and status handling without conflating patient, order and specimen identifiers.
Read model answer +
Use explicit order, specimen, assay and result-version identities. A patient identifier alone is too broad to decide which observation a new message updates.
Work through it
Validate the message envelope and the authorized identifier mappings, quarantining unresolved or conflicting references rather than assigning the nearest matching patient record.
Apply a defined result lifecycle that distinguishes preliminary, final, corrected and cancelled observations, retaining previous versions and their source messages.
Make repeated messages idempotent and expose reconciliation status to the responsible workflow, testing split specimens, repeated assays and delayed corrections.
Tradeoffs to discuss
Strict matching protects identity integrity but increases exception work; fuzzy matching may help propose candidates while requiring reviewed confirmation.
Common pitfalls
Do not replace a final observation with an older preliminary message because it arrived later.
The interface must preserve clinical review authority and avoid displaying technical message acceptance as a medical interpretation.
Original practice scenario: Using synthetic data for a hypothetical diagnostic research classifier, explain how a different outcome prevalence can change precision even if sensitivity and specificity remain similar.
Read model answer +
Precision depends on how common the target outcome is in the evaluated population, as well as the classifier's conditional error rates. One reported metric is therefore not portable to every setting.
Work through it
Define the intended population and reference labels with qualified domain reviewers, separating participants across training and evaluation to avoid repeated-person leakage.
Report sensitivity, specificity, precision and calibration with uncertainty on appropriate held-out data, examining population and measurement differences rather than changing prevalence mechanically.
Compare thresholds only under a stated research decision framework and validate in the target setting before making any clinical-use claim.
Tradeoffs to discuss
A threshold can trade missed outcomes against false positives, but acceptable costs require domain-specific judgment and evidence.
Common pitfalls
Do not present a synthetic prevalence adjustment as prospective clinical validation.
Avoid selecting a threshold on the same data used for its final performance report.
